EZH2 and neoplasm: 3-deazanplanocin A, a histone methylation inhibitor mainly acting via EZH2 inhibition, has been used as an H3K27 methylation reversal agent, and when used as a short pre-treatment to nanoparticle delivered chemotherapeutics induced apoptosis in both well and poorly differentiated tumors and both gemcitabine resistant and sensitive tumor cells [64].